1. Intra-ventral tegmental area or intracerebroventricular orexin-A increases the intra-cranial self-stimulation threshold via activation of the corticotropin-releasing factor system in rats.
- Author
-
Hata T, Chen J, Ebihara K, Date Y, Ishida Y, and Nakahara D
- Subjects
- Amygdala anatomy & histology, Amygdala drug effects, Amygdala physiology, Animals, Corticotropin-Releasing Hormone antagonists & inhibitors, Dopamine metabolism, Infusions, Intraventricular, Intracellular Signaling Peptides and Proteins administration & dosage, Male, Neuropeptides administration & dosage, Neurotransmitter Agents pharmacology, Orexins, Proto-Oncogene Proteins c-fos metabolism, Rats, Rats, Wistar, Reward, Self Stimulation drug effects, Ventral Tegmental Area anatomy & histology, Ventral Tegmental Area physiology, Behavior, Animal drug effects, Corticotropin-Releasing Hormone metabolism, Intracellular Signaling Peptides and Proteins pharmacology, Neuropeptides pharmacology, Self Stimulation physiology, Ventral Tegmental Area drug effects
- Abstract
Although orexin-A peptide was recently found to inhibit the brain reward system, the exact neural substrates for this phenomenon remain unclear. The aim of the present study was to investigate the role of orexin neurons in intra-cranial self-stimulation behavior and to clarify the pathways through which orexin-A inhibits the brain reward system. Immunohistochemical examination using Fos, a neuronal activation marker, revealed that the percentage of activated orexin cells was very low in the lateral hypothalamus even in the hemisphere ipsilateral to self-stimulation, suggesting that orexin neurons play only a small part, if any, in performing intra-cranial self-stimulation behavior. Intra-ventral tegmental area administration of orexin-A (1.0 nmol) significantly increased the intra-cranial self-stimulation threshold. Furthermore, the threshold-increasing effects of intra-ventral tegmental area or intracerebroventricular orexin-A were inhibited by administration of the nonspecific corticotropin-releasing factor receptor antagonist, d-Phe-CRF(12-41) (20 μg). Following intra-ventral tegmental area infusion of orexin-A, the percentage of cells double-labeled with corticotropin-releasing factor and Fos antibodies increased in the central nucleus of the amygdala but not in the bed nucleus of the stria terminalis, and brain microdialysis analyses indicated that dopamine efflux in both the central nucleus of the amygdala and bed nucleus of the stria terminalis were enhanced. Taken together, the present findings suggest that intra-ventral tegmental area or intracerebroventricular administration of orexin-A exerts its threshold-increasing effect via subsequent activation of the corticotropin-releasing factor system., (© 2011 The Authors. European Journal of Neuroscience © 2011 Federation of European Neuroscience Societies and Blackwell Publishing Ltd.)
- Published
- 2011
- Full Text
- View/download PDF